Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2406885 | Vaccine | 2008 | 5 Pages |
Abstract
To augment the available influenza vaccine supply, a phase III study was conducted to evaluate the immunogenicity, safety, and consistency of a new trivalent inactivated influenza vaccine manufactured by CSL Limited. Healthy adults (ages 18–64) were randomized to receive either a single dose of TIV from multi-dose vials with thimerosal, TIV from pre-filled syringes without thimerosal, or placebo. Of the TIV recipients, 97.8% achieved a post-vaccination titer ≥40 against H1N1, 99.9% against H3N2 component, and 94.2% against influenza B. Few local or systemic adverse events were noted after vaccination with either TIV presentation. TIV was well tolerated and immunogenic.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
H. Keipp Talbot, Wendy Keitel, Thomas R. Cate, John Treanor, James Campbell, Rebecca C. Brady, Irene Graham, Cornelia L. Dekker, Dora Ho, Patricia Winokur, Emmanuel Walter, Jillian Bennet, Neil Formica, Gunter Hartel, Maryanne Skeljo, Kathryn M. Edwards,